Geographic variations in the PARADIGM-HF heart failure trial

European Heart Journal

Volumn 37, Issue 41, 2016, Pages 3167-3174

  Kristensen, Søren Lund ^a,b   Martinez, Felipe ^c   Jhund, Pardeep S ^a   Arango, Juan Luis ^d   Belohlavek, Jan ^e   Boytsov, Sergey ^f   Cabrera, Walter ^g   Gomez, Efrain ^h   Hagège, Albert A ⁱ   Huang, Jun ^j   Kiatchoosakun, Songsak ^k   Kim, Kee Sik ^l   Mendoza, Iván ^m   Senni, Michele ⁿ   Squire, Iain B ^o   Vinereanu, Dragos ^p   Wong, Raymond Ching Chiew ^q   Gong, Jianjian ^r   Lefkowitz, Martin P ^r   Rizkala, Adel R ^r   Rouleau, Jean L ^s   Shi, Victor C ^r   Solomon, Scott D ^t   Swedberg, Karl ^u,v   Zile, Michael R ^w   Packer, Milton ^x   McMurray, John J V ^a   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^d Guatemalan Heart Institute   (Guatemala)

^e CHARLES UNIVERSITY   (Czech Republic)

^f NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

^g Clinica Vesalio   (Peru)

^h Division of Cardiovascular Surgery   (Colombia)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j NANJING MEDICAL UNIVERSITY   (China)

^k KHON KAEN UNIVERSITY   (Thailand)

^l Catholic University of Daegu   (South Korea)

^m UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

ⁿ Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^o UNIVERSITY OF LEICESTER   (United Kingdom)

^p CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^q NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^r NOVARTIS PHARMA AG   (Switzerland)

^s MONTREAL HEART INSTITUTE   (Canada)

^t BRIGHAM AND WOMEN S HOSPITAL   (United States)

^u UNIVERSITY OF GOTHENBURG   (Sweden)

^v NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^w MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^x BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Clinical trial; Geographical variation; Heart failure; Prognosis; Treatment outcome

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; ENALAPRIL; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; SACUBITRIL PLUS VALSARTAN;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CLINICAL OUTCOME; COMORBIDITY; CORONARY ARTERY DISEASE; COUGHING; DEATH; DRUG WITHDRAWAL; EASTERN EUROPE; FEMALE; FUNCTIONAL STATUS; GEOGRAPHY; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORTH AMERICA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RUSSIAN FEDERATION; SOUTH AND CENTRAL AMERICA; WESTERN EUROPE; ASIA; EUROPE; MIDDLE AGED;

AGED; ASIA; EUROPE; HEART FAILURE; HOSPITALIZATION; HUMANS; MIDDLE AGED;

EID: 85015912024     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw226     Document Type: Article

References (24)

1. Rush CJ, Campbell RT, Jhund PS, Connolly EC, Preiss D, Gardner RS, Petrie MC, McMurray JJ. Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC Heart Fail 2015;3:603-614.
2. O'Connor CM. The globalization of heart failure research. JACC Heart Fail 2015;3:657-658.
3. Wedel H, Demets D, Deedwania P, Fagerberg B, Goldstein S, Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J, MERIT-HF Study Group. Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. Am Heart J 2001;142:502-511.
4. Massie BM, Cleland JG, Armstrong PW, Horowitz JD, Packer M, Poole-Wilson PA, Ryden L. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. J Card Fail 1998;4:3-8.
5. Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, Freemantle N, Gavazzi A, van Gilst WH, Hobbs FD, Korewicki J, Madeira HC, Preda I, Swedberg K, Widimsky J, IMPROVEMENT of Heart Failure Programme Committees and Investigators. Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): An international survey. Lancet 2002;360:1631-1639.
6. Sturm HB, van Gilst WH, Veeger N, Haaijer-Ruskamp FM. Prescribing for chronic heart failure in Europe: Does the country make the difference? A European survey. Pharmacoepidemiol Drug Saf 2007;16:96-103.
7. Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JCJr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M, EVEREST Investigators. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol 2008;52:1640-1648.
8. Howlett JG, Ezekowitz JA, Podder M, Hernandez AF, Diaz R, Dickstein K, Dunlap ME, Corbalán R, Armstrong PW, Starling RC, O'Connor CM, Califf RM, Fonarow GC, ASCEND-HF Investigators. Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: Findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). Circ Cardiovasc Qual Outcomes 2013;6:534-542.
9. Pitt B, Gheorghiade M. Geographic variation in heart failure trials: Time for scepticism?. Eur J Heart Fail 2014;16:601-602.
10. Mentz RJ, Cotter G, Cleland JG, Stevens SR, Chiswell K, Davison BA, Teerlink JR, Metra M, Voors AA, Grinfeld L, Ruda M, Mareev V, Lotan C, Bloomfield DM, Fiuzat M, Givertz MM, Ponikowski P, Massie BM, O'Connor CM. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: Better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail 2014;16:614-624.
11. Greene SJ, Fonarow GC, Solomon SD, Subacius H, Maggioni AP, Böhm M, Lewis EF, Zannad F, Gheorghiade M, ASTRONAUT Investigators and Coordinators. Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: Findings from the ASTRONAUT trial. Eur J Heart Fail 2015;17:591-600.
12. Kristensen SL, Køber L, Jhund PS, Solomon SD, Kjekshus J, McKelvie RS, Zile MR, Granger CB, Wikstrand J, Komajda M, Carson PE, Pfeffer MA, Swedberg K, Wedel H, Yusuf S, McMurray JJ. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation 2015;131:43-53.
13. Ferreira JP, Girerd N, Rossignol P, Zannad F. Geographic differences in heart failure trials. Eur J Heart Fail 2015;9:893-905.
14. Poole-Wilson PA. Global differences in the outcome of heart failure: Implications for clinical practice. J Am Coll Cardiol 2008;52:1649-1651.
15. O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, Gattis- Stough W, Davis GW, Bristow MR. Influence of global region on outcomes in heart failure b-blocker trials. J Am Coll Cardiol 2011;58:915-922.
16. Chatterjee S, Udell JA, Sardar P, Lichstein E, Ryan JJ. Comparable benefit of bblocker therapy in heart failure across regions of the world: Meta-analysis of randomized clinical trials. Can J Cardiol 2014;30:898-903.
17. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015;131:34-42.
18. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
19. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: Rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013;15: 1062-1073.
20. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Committees Investigators. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 2014;16: 817-825.
21. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, McCullough PA, Pina I, Tooley J, Weintraub WS, Rumsfeld JS, Cardiovascular Outcomes Research Consortium. Monitoring clinical changes in patients with heart failure: A comparison of methods. Am Heart J 2005;150:707-715.
22. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 2014;11:639-654.
23. Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: Analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure). J Am Coll Cardiol 2013;62:1585-1593.
24. Chen CH, Chen MC, Gibbs H, Kwon SU, Lo S, On YK, Rosman A, Suwanwela NC, Tan RS, Tirador LS, Zirlik A. Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda. Int J Cardiol 2015;191:244-253.